CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Recruiting · NCT06834282 · Registry updated 2026-08-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-08-26 | NCT06834282 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CERo Therapeutics Holdings, Inc. | 1 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Colorado Blood Cancer Institute | Denver | United States | 178 |
| Fred Hutchinson Cancer Center | Seattle | United States | 250 |
| Sarah Cannon Research Insitute | Nashville | United States | 2 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |
| University of California, Davis Comprehensive Cancer Center | Sacramento | United States | 18 |